Your browser doesn't support javascript.
loading
Unfractionated heparin reverses aspirin inhibition of platelets during coronary artery bypass graft surgery.
Turnbull, Robert E; Hafeez, Azhar; Sander, Katrin N; Barrett, David A; Murphy, Gavin J; Goodall, Alison H.
Affiliation
  • Turnbull RE; Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, Glenfield Hospital, Leicester, UK. ret28@leicester.ac.uk.
  • Hafeez A; The Leicester Institute of Structural and Chemical Biology and Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, Leicester, LE1 7HB, UK. ret28@leicester.ac.uk.
  • Sander KN; Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
  • Barrett DA; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2HQ, UK.
  • Murphy GJ; Centre for Analytical Bioscience, Advanced Materials and Healthcare Division, School of Pharmacy, University of Nottingham, Nottingham, UK.
  • Goodall AH; Centre for Analytical Bioscience, Advanced Materials and Healthcare Division, School of Pharmacy, University of Nottingham, Nottingham, UK.
Sci Rep ; 14(1): 8572, 2024 04 13.
Article in En | MEDLINE | ID: mdl-38609431
ABSTRACT
Unfractionated heparin (UFH) is an effective antithrombotic during surgery but has known adverse effects, in particular on platelets. A marked increase in platelet responsiveness has previously been observed in patients within minutes of receiving UFH, despite adequate inhibition by aspirin prior to heparin. We studied this phenomenon in patients undergoing cardiac artery bypass grafting (n = 17) to determine whether the effects of heparin were systemic or platelet-specific. All patients' platelets were fully inhibited by aspirin prior to surgery, but within 3 min of receiving heparin spontaneous aggregation and responses to arachidonic acid (AA) and ADP increased significantly (p ≥ 0.0002), and activated platelets were found in the circulation. While there was no rise in thromboxane in the plasma following heparin, levels of the major platelet 12-lipoxygenase product, 12-HETE, rose significantly. Mixing experiments demonstrated that the changes caused by heparin resided primarily in the platelets, while addition of AA pathway inhibitors, and analysis of oxylipins provided evidence that, following heparin, aggregating platelets regained their ability to synthesise thromboxane. These findings highlight potentially unrecognised pro-thrombotic and pro-inflammatory changes during CABG surgery, and provide further evidence of adverse effects associated with UFH.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heparin / Drug-Related Side Effects and Adverse Reactions Limits: Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heparin / Drug-Related Side Effects and Adverse Reactions Limits: Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country: